{"slideshow_credits": null, "snippet": "Experimental treatments use an antibody to guide a toxic chemotherapy agent to cancer cells, limiting the toxin\u2019s attack to the cancer and minimizing side effects.", "abstract": "Experimental treatments use an antibody to guide a toxic chemotherapy agent to cancer cells, limiting the toxin\u2019s attack to the cancer and minimizing side effects; it is the harbinger of a new class of cancer drugs that may be more effective and less toxic than many existing treatments; treatment, called T-DM1, may reach the market in 2013.", "section_name": "Business Day", "print_page": "1", "document_type": "article", "byline": {"person": [{"firstname": "Andrew", "role": "reported", "lastname": "POLLACK", "rank": 1, "organization": ""}], "original": "By ANDREW POLLACK", "contributor": ""}, "web_url": "http://www.nytimes.com/2012/06/01/business/a-new-class-of-cancer-drugs-may-be-less-toxic.html", "lead_paragraph": "Experimental treatments use an antibody to guide a toxic chemotherapy agent to cancer cells, limiting the toxin\u2019s attack to the cancer and minimizing side effects.", "headline": {"seo": "A New Class of Cancer Drugs May Be Less Toxic", "main": "A New Class of Cancer Drugs May Be Less Toxic", "print_headline": "A One-Two Punch"}, "_id": "53f7599e38f0d821a37b2e5d", "word_count": "1199", "multimedia": [{"height": 370, "url": "images/2012/06/01/business/CANCER/CANCER-articleLarge.jpg", "legacy": {"xlarge": "images/2012/06/01/business/CANCER/CANCER-articleLarge.jpg", "xlargewidth": "600", "xlargeheight": "370"}, "subtype": "xlarge", "width": 600, "type": "image"}, {"height": 75, "url": "images/2012/06/01/business/CANCER/CANCER-thumbStandard.jpg", "legacy": {"thumbnail": "images/2012/06/01/business/CANCER/CANCER-thumbStandard.jpg", "thumbnailwidth": "75", "thumbnailheight": "75"}, "subtype": "thumbnail", "width": 75, "type": "image"}], "pub_date": "2012-06-01T00:00:00Z", "source": "The New York Times", "news_desk": "Business", "keywords": [{"value": "Cancer", "name": "subject", "is_major": "Y", "rank": "1"}, {"value": "Drugs (Pharmaceuticals)", "name": "subject", "is_major": "N", "rank": "2"}, {"value": "Chemotherapy", "name": "subject", "is_major": "Y", "rank": "3"}, {"value": "Antibodies", "name": "subject", "is_major": "N", "rank": "4"}, {"value": "Research", "name": "subject", "is_major": "N", "rank": "5"}, {"value": "ImmunoGen Inc", "name": "organizations", "is_major": "N", "rank": "6"}, {"value": "Seattle Genetics", "name": "organizations", "is_major": "N", "rank": "7"}, {"value": "Biotechnology", "name": "subject", "is_major": "N", "rank": "8"}, {"value": "Genentech Inc", "name": "organizations", "is_major": "N", "rank": "9"}], "blog": [], "subsection_name": null, "type_of_material": "News"}